Research Papers:

COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma

Lu Zheng, Chang-Lin Deng, Liang Wang, Xiao-Bing Huang, Nan You, Yi-Chen Tang, Ke Wu, Ping Liang, Na Mi and Jing Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:32774-32784. https://doi.org/10.18632/oncotarget.9047

Metrics: PDF 1751 views  |   HTML 2005 views  |   ?  


Lu Zheng1, Chang-Lin Deng1, Liang Wang1, Xiao-Bing Huang1, Nan You1, Yi-Chen Tang1, Ke Wu1, Ping Liang1, Na Mi1, Jing Li1

1Department of Hepatobiliary Surgery, Xinqiao Hospital of Third Military Medical University, Chongqing, 400037, China

Correspondence to:

Jing Li, email: [email protected]

Keywords: COMMD7, nuclear factor-kappa B, proliferation, apoptosis, hepatocellular carcinoma

Received: October 20, 2015     Accepted: March 31, 2016     Published: April 27, 2016


The correlation between nuclear factor-kappa B (NF-κB) and COMMD7 in hepatocellular carcinoma (HCC) development remained unclear. Here, our clinicopathological data showed that COMMD7 is overexpressed in HCC with a correlation to NF-κB. Using HepG2 and SMMC-7721 cells that aberrantly overexpressed COMMD7, we found that NF-κB directly binds with COMMD7 promoter and serves as an activator for COMMD7 transcription by luciferase reporter assay, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA). In both HepG2 cells and SMMC-7721 cells, the silencing of COMMD7 significantly inhibited the cell proliferation, whereas NF-κB silencing inhibited the expression of COMMD7 and further inhibited cell proliferation. In addition, cell apoptosis was promoted by COMMD7 silencing, and further promoted by NF-κB silencing. Cell migration and invasion were also inhibited by COMMD7 silencing, and further inhibited by NF-κB silencing. Thus, COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma. Developing strategies for the treatment of HCC should consider the correlation between NF-κB and COMMD7, so as to improve the specificity and sensitivity of therapy and to reduce toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9047